Christine A. Poon - 09 Aug 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/** Christine A. Poon
Issuer symbol
REGN
Transactions as of
09 Aug 2022
Net transactions value
-$6,646,299
Form type
4
Filing time
11 Aug 2022, 16:09:31 UTC
Previous filing
12 Jul 2022
Next filing
19 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $2,667,300 +15,000 +801% $177.82 16,872 09 Aug 2022 Direct
transaction REGN Common Stock Sale $4,227,883 -6,814 -40% $620.47 10,058 09 Aug 2022 Direct F1
transaction REGN Common Stock Sale $5,085,716 -8,186 -81% $621.27 1,872 09 Aug 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -15,000 -100% $0.000000* 0 09 Aug 2022 Common Stock 15,000 $177.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 6,814 shares of Company stock on August 9, 2022 at prices ranging from $620.20 to $620.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2022 at each separate price.
F2 Represents volume-weighted average price of sales of 8,186 shares of Company stock on August 9, 2022 at prices ranging from $621.01 to $621.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 9, 2022 at each separate price.
F3 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.